Samsung Bio surpasses 바카라 에볼루션 2 trillion in H1 sales ahead of transformation to ‘dedicated CDMO’ business

[by Ji, Yong Jun] Samsung Biologics continued its upward trajectory in performance during the second quarter, driven by the ramp-up (increased operational capacity) of Plant 4, the world's largest biopharmaceutical production facility, and robust sales within its biosimilar business segment. The company, which is slated for a spin-off in H2 2025, anticipates continued momentum as a dedicated contract development and manufacturing organization (CDMO), having exceeded 바카라 에볼루션 2 trillion (approximately USD 1.4 billion) in standalone sales during H1 for the first time since its founding. Reflecting this positive outlook, Samsung Biologics revised its annual sales forecast upward to 바카라 에볼루션 5.7978 trillion, representing a 5 percentage point (%p) increase in projected growth compared to the previous estimate.

Samsung Biologics reported on July 23 a 9.5% year-on-year increase in consolidated operating profit for Q2, reaching 바카라 에볼루션 475.6 billion (approximately USD 346.3 million). Preliminary results also indicate that sales rose by 11.5% to 바카라 에볼루션 1.2899 trillion, while net profit grew by 2.0% to 바카라 에볼루션 324.4 billion during the same period. As a result, the company recorded consolidated sales of 바카라 에볼루션 2.5882 trillion and an operating profit of 바카라 에볼루션 962.3 billion in the first half of the year, marking respective increases of 23.0% and 46.7% compared to the same period in 2024.

Samsung Biologics exceeded 바카라 에볼루션 2 trillion in standalone sales for the first half of the year, marking the highest first-half performance since its establishment. H1 sales reached 바카라 에볼루션 2.138 trillion, reflecting a year-on-year increase of 36.1%, while operating profit rose by 61.4% to 바카라 에볼루션 907.1 billion.

A key driver of Samsung Biologics’ performance growth has been the strong execution of CMO orders. The company has secured contracts with 17 of the world’s top 20 global pharmaceutical companies by market capitalization. In line with its strategy to expand its client base, Samsung Biologics initiated plans earlier this year to target the top 40 global pharmaceutical companies by opening a sales office in Tokyo, Japan, thereby expanding its contact points with customers in the Asian market. During the first half of the year alone, the company recorded cumulative orders totaling KRW 3.355 trillion, representing approximately 62% of its total order volume for the previous year (KRW 5.4035 trillion).

On this day, Samsung Biologics revised its annual sales growth forecast upward from the previously estimated range of 20-25% to 25-30%, reflecting an anticipated additional growth of 5%p in just six months since the initial projection made in January.

Samsung Biologics' revision of its annual guidance upward within just six months is attributed to its 'three-axis strategy,' focused on expanding production capacity, diversifying its portfolio, and strengthening its global bases. Leveraging the world’s largest biopharmaceutical production capacity, the company has been consistently maintaining a favorable global order performance. The completion of Plant 5 in April, with a capacity of 180,000 liters (ℓ), brought Samsung Biologics’ total production capacity to784,000 ℓ. Building on this momentum, the company plans to build three additional plants (Plants 6 through 8) at its Second Bio Campus, thereby reinforcing its position as a global leader in biomanufacturing capacity.

Samsung Bioepis, a wholly owned subsidiary of Samsung Biologics, recorded sales of 바카라 에볼루션 801.6 billion (approximately USD 583.6 million) and an operating profit of 바카라 에볼루션 217.8 billion in H1 2025. This performance was driven by the expansion of biosimilar product sales in the global market, including the successful launch of two new products in the United States.

In Q2, Samsung Bioepis recorded sales of 바카라 에볼루션 401.0 billion and an operating profit of 바카라 에볼루션 89.8 billion, representing year-on-year declines of 24.3% and 65.1%, respectively, compared to the same period last year. The company attributed this decrease to a base effect resulting from the temporary reflection of 바카라 에볼루션 220.5 billion in milestone payments (compensation for research and development performance) during Q2 2024. When excluding this one-time revenue, sales for Q2 actually increased by 28% compared to the previous year.

Meanwhile, Samsung Biologics is advancing preparations for a corporate spin-off with the establishhment of ‘Samsung Epi Holdings’ in the second half of the year. In May, the company announced its plan to fully separate its ‘biopharmaceutical CDMO operations’ from its ‘biosimilar business.’ Through this structural reorganization, Samsung Biologics aims to solidify its identity as a pure-play CDMO and to further strengthen trust and partnerships with its client base.

As of the end of the second quarter, Samsung Biologics reported consolidated assets totaling 바카라 에볼루션 17.7736 trillion, with capital amounting to 바카라 에볼루션 11.6028 trillion and liabilities of 바카라 에볼루션 6.1709 trillion. The company maintained a stable financial position, reflected in a debt ratio of 53.2% and a borrowing ratio of 11.6%.